HIV protease inhibitors
US9737545B2 · kind B2 · utility
0Cited by
8References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 17, 2014 |
| Grant date | Aug 22, 2017 |
| Priority date | — |
| Expiry date | Dec 17, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.